• Hexetidine (NSC-17764): Synergy, Pharmacodynamics, and Assay

  2026-08-05

  Explore the advanced pharmacodynamics and unique synergistic properties of Hexetidine (NSC-17764) as an antibacterial agent for oral infections. This article uncovers new in vitro strategies and practical insights not found in standard reviews.

• Tumor-Targeted PAD4 Inhibition via m-PBA: Mechanistic Advanc

  2026-08-04

  This study introduces a meta-phenylboronic acid-modified PAD4 inhibitor, Compound 5i TFA, enabling highly selective, tumor-targeted inhibition of the PAD4–H3cit–NETs pathway. These findings reveal a new mechanism for suppressing tumor growth and metastasis through precise immune modulation with minimal toxicity.

• MG-132 (Z-LLL-al): Applied Protocols for Apoptosis & Cell Cy

  2026-08-04

  MG-132 (Z-LLL-al) stands out as a potent, cell-permeable proteasome inhibitor optimized for apoptosis assays, cell cycle arrest studies, and oxidative stress research. This guide translates recent mechanistic insights and best practices into actionable workflows, troubleshooting tips, and future directions for maximizing reproducibility and scientific impact.

• Fluorescein TSA Fluorescence System Kit: Signal Amplificatio

  2026-08-03

  The Fluorescein TSA Fluorescence System Kit enables ultrasensitive detection of low-abundance biomolecules through robust signal amplification. By leveraging horseradish peroxidase-catalyzed deposition of fluorescein-labeled tyramide, the kit delivers high-density fluorescent labeling ideal for immunohistochemistry, immunocytochemistry, and in situ hybridization. This product is validated for improved sensitivity and reproducibility compared to conventional fluorescence protocols.

• CDK9 Inhibitor (A3294): Technical Guidance and Lab Protocols

  2026-08-03

  CDK9 inhibitor (A3294) provides researchers with a selective, non-cytotoxic tool for targeted inhibition of cyclin dependent kinase 9, supporting transcription elongation and HIV-1 propagation studies. It is not suitable for broad-spectrum CDK inhibition or protocols requiring long-term storage of working solutions.

• Bafilomycin A1: V-ATPase Inhibitor for Advanced Cell Biology

  2026-08-02

  Bafilomycin A1 empowers researchers with precise, reversible V-ATPase inhibition—unlocking nuanced interrogation of intracellular pH, lysosomal, and mitophagy pathways. Discover protocol-focused strategies, troubleshooting, and data-driven insights to maximize reproducibility in lysosomal function and infectious disease research using APExBIO’s high-quality reagent.

• Nanoparticle Uptake in Corneal Cells: Size and Surface Effec

  2026-08-01

  This study by Azadi and David systematically investigates how the physicochemical properties of PLGA nanoparticles—specifically size and surface chemistry—influence their uptake by human corneal epithelial cells. The findings clarify that energy-dependent endocytic pathways, especially macropinocytosis and caveolae-mediated endocytosis, dominate cellular internalization, providing a strong mechanistic basis for rational design of ocular drug delivery systems.

• OSMI-1: Precision O-GlcNAc Transferase Inhibitor for Cell St

  2026-07-31

  OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor with an IC50 of 2.7 μM, enabling reliable modulation of protein O-GlcNAcylation in vitro and in vivo. Its high purity and documented effects on cellular viability and protein modification underpin its role in mechanistic studies. APExBIO supplies OSMI-1 for research requiring precise O-GlcNAcylation control.

• Benchmarking LNP Platforms for Firefly Luciferase mRNA Deliv

  2026-07-31

  This study systematically compares four bench-scale lipid nanoparticle (LNP) mixing platforms for encapsulating mRNA, including firefly luciferase constructs, under standardized conditions. The findings illuminate which micromixing technologies yield superior particle uniformity, encapsulation efficiency, and in vivo protein expression—key determinants for reliable mRNA vaccine research and functional reporter gene assays.

• Astragaloside IV Attenuates Diabetic Cardiomyopathy via TLR4

  2026-07-30

  This study demonstrates that astragaloside IV reduces inflammation and apoptosis in diabetic cardiomyopathy by inhibiting the TLR4/MyD88/NF-κB pathway. The findings highlight a mechanistic basis for targeting TLR4 signaling in cardiac metabolic disease models, with implications for translational research and future therapeutic development.

• Palmitic acid (Hexadecanoic Acid): Technical Use and Protoco

  2026-07-30

  Palmitic acid (hexadecanoic acid, SKU N2456) is a high-purity, well-characterized saturated long-chain fatty acid essential for reproducible in vitro research on lipid metabolism, metabolic disorder pathways, and protein palmitoylation. It is not suitable for aqueous-based assays or workflows requiring long-term solution stability, necessitating precise non-aqueous handling and storage to maintain experimental consistency.

• Linking High-Throughput Screens to MoA Discovery in M. tuber

  2026-07-29

  Santa Maria et al. introduce a machine learning-integrated framework that connects phenotypic and target-based high-throughput screens to systematically identify mechanisms of action and new inhibitors for bacterial targets, exemplified by Mycobacterium tuberculosis dihydrofolate reductase. This approach advances antibacterial discovery by enabling precise target deconvolution and identification of compounds with selective bacterial efficacy.

• Technical Guidance for Using Angiotensin I/II (1-5) in RAS R

  2026-07-29

  Angiotensin I/II (1-5) provides researchers with a defined Asp-Arg-Val-Tyr-Ile peptide fragment for targeted study of blood pressure regulation and aldosterone signaling within the renin-angiotensin system. It is best suited to cardiovascular and renal research workflows and should not be applied to unrelated peptide signaling studies due to its specific biochemical properties.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual-Reporter mRNA Delivery

  2026-07-28

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers researchers to track both mRNA delivery and protein expression in real time, bridging the gap between nanoparticle formulation and functional readout. Its dual-fluorescent, immune-evasive design sets a new standard for quantitative transfection and translation efficiency assays.

• Triple Color Protein Ladders: Accelerating Translational Imp

  2026-07-28

  Explore how the next generation of Prestained Protein Markers—anchored by mechanistic insight and rigorous benchmarking—are transforming translational research, from molecular discovery to clinical readiness. Learn why strategic marker selection, evidenced by recent LARP1-ribosome studies, is pivotal for reproducibility, transfer efficiency, and workflow agility.

452 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page